Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects With Severe Hemophilia A

NCT02172950 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT02172950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02172950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects With Severe Hemophilia A
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Completed
Start date
October 13, 2014
Completion date
January 19, 2021
Enrollment
246 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a, severe hemophilia a